H. Lundbeck Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Charl van Zyl

Chief executive officer

DKK 39.6m

Total compensation

CEO salary percentage	6.8%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.8yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Charl van Zyl's remuneration changed compared to H. Lundbeck's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	DKK 2b
Dec 31 2023	DKK 40m	DKK 3m	DKK 2b

Compensation vs Market: Charl's total compensation ($USD5.69M) is above average for companies of similar size in the Austrian market ($USD2.06M).

Compensation vs Earnings: Insufficient data to compare Charl's compensation with company performance.

CEO

Charl van Zyl (57 yo)

less than a year

Tenure

DKK 39,600,000

Compensation

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charl van Zyl	President & CEO	less than a year	DKK 39.60m	no data
Joerg Hornstein	CFO & Executive VP of Corporate Functions	1.8yrs	DKK 10.90m	0.0023% DKK 114.0k
Lars Bang	Executive Vice President of Product Development & Supply	5.4yrs	DKK 10.10m	0.038% DKK 1.9m
Per Luthman	Executive Vice President of Research & Development	5.4yrs	DKK 11.30m	0.014% DKK 702.2k
Tarek Samad	Senior VP & Head of Research	3.1yrs	no data	no data
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	no data	no data
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	no data	no data
Dianne Holto	Executive Vice President of People & Organization	less than a year	no data	no data
Ole Chrintz	Senior Vice President of International Markets	no data	no data	no data
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.4yrs	no data	no data
Bjorn Mogensen	Senior Vice President of Group Finance	1.8yrs	no data	no data
Jose Molinuevo	VP & Head of Experimental Medicine	no data	no data	no data

1.8yrs

Average Tenure

58.5yo

Average Age

Experienced Management: LUNA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Lars Rasmussen	Independent Chairman	11.4yrs	DKK 1.70m	0.010% DKK 506.3k
Lene Skole-Sorensen	Deputy Chairman	9.4yrs	DKK 1.20m	0.0062% DKK 310.4k
Jeffrey Berkowitz	Independent Director	6.3yrs	DKK 1.20m	no data
Lars Holmqvist	Director	9.4yrs	DKK 600.00k	0.0076% DKK 379.7k
Jakob Riis	Director	1.3yrs	DKK 450.00k	0.0055% DKK 274.2k
Ilse Wenzel	Independent Director	3.3yrs	DKK 70.00k	no data
Santiago Arroyo	Independent Director	3.3yrs	DKK 1.00m	no data
Camilla Andersson	Employee Representative Director	2.3yrs	DKK 400.00k	0.00010% DKK 5.0k
Dorte Clausen	Employee Representative Director	2.3yrs	DKK 400.00k	0.00011% DKK 5.5k
Hossein Armandi	Employee Representative Director	2.3yrs	DKK 400.00k	no data
Lasse Skibsbye	Employee Representative Director	2.3yrs	DKK 400.00k	no data

3.3yrs

Average Tenure

58yo

Average Age

Experienced Board: LUNA's board of directors are considered experienced (3.3 years average tenure).

H. Lundbeck Management

Management criteria checks 1/4

Key information

Recent management updates

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

Less than half of directors are independent

Recent updates

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Full year 2023 earnings released

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

Third quarter 2023 earnings released

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Second quarter 2023 earnings released: EPS: kr.0.60 (vs kr.0.51 in 2Q 2022)

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

Less than half of directors are independent

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age